XML 51 R39.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Concentration Risk [Line Items]      
Rebate receivable $ 33,900   $ 54,400
Investments in equity-method investees 26,200   $ 24,500
Equity in earnings of joint ventures 1,729 $ 1,125  
Distributions received from the investees $ 0 750  
Joint Venture      
Concentration Risk [Line Items]      
Distributions received from the investees   $ 800  
Revenue from Contract with Customer Benchmark | Company's Largest Payer | Largest Payer      
Concentration Risk [Line Items]      
Concentration ​risk 15.00% 14.00%  
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs      
Concentration Risk [Line Items]      
Concentration ​risk 12.00% 12.00%  
Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs      
Concentration Risk [Line Items]      
Concentration ​risk 11.00%   11.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors      
Concentration Risk [Line Items]      
Concentration ​risk 66.00% 66.00%